2105744368932a2d2ccf7c1786f339a5 247488.pdf 430474149737eb0013ece34d5538064abfca2628 247488.pdf 86f7efda0006a533e2bc50cc999cb0aaf6505f7054f5d5ab317653663f54fb07 247488.pdf Title: COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease Subject: Introduction: Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Methods: Data included patients who underwent kidney biopsy at the Vall d’Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Results: Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO­VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Conclusions: Patients with CO­VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality. Author: Román J.L.; García-Carro C.; Agraz I.; Toapanta N.; Vergara A.; Gabaldón A.; Torres I.; Bury R.; Baldallo C.; Serón D.; Soler M.J. Creator: Adobe InDesign 16.3 (Windows) Producer: Adobe PDF Library 15.0 CreationDate: Fri Aug 20 06:57:58 2021 CEST ModDate: Fri Aug 20 06:57:59 2021 CEST Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 8 Encrypted: no Page size: 595.276 x 793.701 pts Page rot: 0 File size: 264107 bytes Optimized: yes PDF version: 1.4 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- WGNZVW+MyriadPro-Bold Type 1C WinAnsi yes yes yes 227 0 SIIWRE+MyriadPro-Regular Type 1C WinAnsi yes yes yes 228 0 JFVUVW+MinionPro-Regular Type 1C Custom yes yes yes 237 0 KZGVJU+MyriadPro-BoldIt Type 1C WinAnsi yes yes yes 238 0 VATEHY+MyriadPro-It Type 1C WinAnsi yes yes yes 239 0 RPQGDG+MinionPro-It Type 1C WinAnsi yes yes yes 185 0 JFVUVW+MinionPro-Regular Type 1C WinAnsi yes yes yes 183 0 JFVUVW+MinionPro-Regular Type 1C WinAnsi yes yes yes 182 0 KHEQJU+MinionPro-Bold Type 1C WinAnsi yes yes yes 192 0 IEFEHY+Cambria TrueType WinAnsi yes yes yes 197 0 JFVUVW+MinionPro-Regular Type 1C WinAnsi yes yes yes 195 0 JFVUVW+MinionPro-Regular Type 1C WinAnsi yes yes yes 194 0 IEFEHY+SegoeUI TrueType WinAnsi yes yes yes 206 0 Jhove (Rel. 1.22.1, 2019-04-17) Date: 2022-03-25 02:28:33 CET RepresentationInformation: 247488.pdf ReportingModule: PDF-hul, Rel. 1.12.1 (2019-04-17) LastModified: 2022-03-24 13:28:44 CET Size: 264107 Format: PDF Version: 1.4 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf Profile: Linearized PDF, ISO PDF/A-1, Level B PDFMetadata: Objects: 262 FreeObjects: 1 IncrementalUpdates: 1 DocumentCatalog: ViewerPreferences: HideToolbar: false HideMenubar: false HideWindowUI: false FitWindow: false CenterWindow: false DisplayDocTitle: false NonFullScreenPageMode: UseNone Direction: L2R ViewArea: CropBox ViewClip: CropBox PrintArea: CropBox PageClip: CropBox PageLayout: SinglePage PageMode: UseNone Language: de-DE Outlines: Item: Title: startTableBody Item: Title: startTableBody Item: Title: startTableBody Item: Title: startTableBody Info: Title: COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease Author: Román J.L.; García-Carro C.; Agraz I.; Toapanta N.; Vergara A.; Gabaldón A.; Torres I.; Bury R.; Baldallo C.; Serón D.; Soler M.J. Subject: Introduction: Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospi琀愀氀椀稀愀琀椀漀渀 愀渀搀 搀攀愀琀栀⸀ 吀栀攀 瀀爀漀最渀漀猀椀猀 愀渀搀 氀攀琀栀愀氀椀琀礀 漀昀 䌀伀嘀䤀䐀ⴀ㄀㤀 椀渀昀攀挀琀椀漀渀 椀渀 瀀愀琀椀攀渀琀猀 眀椀琀栀 攀猀琀愀戀氀椀猀栀攀搀 欀椀搀渀攀礀 搀椀猀攀愀猀攀 栀愀猀 渀漀琀 戀攀攀湜ഀ 眀椀搀攀氀礀 猀琀甀搀椀攀搀⸀ 䴀攀琀栀漀搀猀㨀 䐀愀琀愀 椀渀挀氀甀搀攀搀 瀀愀琀椀攀渀琀猀 眀栀漀 甀渀搀攀爀眀攀渀琀 欀椀搀渀攀礀 戀椀漀瀀猀礀 愀琀 琀栀攀 嘀愀氀氀 搠ᤀ䠀攀戀爀漀渀 䠀漀猀瀀椀琀愀氀 戀攀琀眀攀攀渀 䨀愀渀甀愀爀礀 ㈀　㄀㌀and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Results: Thirty-nine (7%) patients w攀爀攀 搀椀愀最渀漀猀攀搀 眀椀琀栀 䌀伀嘀䤀䐀ⴀ㄀㤀 椀渀昀攀挀琀椀漀渀⸀ 䴀攀愀渀 愀最攀 眀愀猀 㘀㌀ 넀 ㄀㔀 礀攀愀爀猀 愀渀搀 㐀㠀⸀㜀─ 眀攀爀攀 洀愀氀攀⸀ 䠀礀瀀攀爀琀攀渀猀椀漀渀 眀愀猀 瀀爀攀猀攀渀琀 椀渀 㜀㤀⸀㔀─Ⰰ 䌀䬀䐀 眀thout renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients㬀 漀氀搀攀爀 瀀 㴀 　⸀　㄀Ⰰ 栀礀瀀攀爀琀攀渀猀椀瘀攀 瀀 㴀 　⸀　　㔀Ⰰ 愀渀搀 椀洀洀甀渀漀猀甀瀀瀀爀攀猀猀攀搀 瀀 㴀 　⸀　㄀ 瀀愀琀椀攀渀琀猀Ⰰ 琀栀漀猀攀 甀猀椀渀最 刀䄀匀ⴀ戀氀漀挀欀椀渀最 搀爀甀最猀 瀀 㴀⁜ഀ　⸀　㐀Ⰰ 愀渀搀 琀栀漀猀攀 眀椀琀栀 最愀猀琀爀漀椀渀琀攀猀琀椀渀愀氀 猀礀洀瀀琀漀洀猀 瀀 㴀 　⸀　㈀ 眀攀爀攀 洀漀爀攀 氀椀欀攀氀礀 琀漀 戀攀 琀攀猀琀攀搀 昀漀爀 䌀伀관嘀䤀䐀ⴀ㄀㤀⸀ 吀眀攀渀琀礀ⴀ琀眀漀 瀀愀琀椀攀渀琀猀 爀敜ഀ焀甀椀爀攀搀 栀漀猀瀀椀琀愀氀椀稀愀琀椀漀渀 愀渀搀 ㄀㔀⸀㐀─ 搀椀攀搀⸀ 䤀渀 戀椀瘀愀爀椀愀琀攀 愀渀愀氀礀猀椀猀Ⰰ 洀漀爀琀愀氀椀琀礀 眀愀猀 愀猀猀漀挀椀愀琀攀搀 眀椀琀栀 漀氀搀攀爀 愀最攀 瀀 㴀 　⸀　㌀Ⰰ 挀愀爀搀椀漀瘀愀猀挀甀氀r disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox 爀攀最爀攀猀猀椀漀渀 猀栀漀眀攀搀 琀栀愀琀 氀漀眀 栀攀洀漀最氀漀戀椀渀 氀攀瘀攀氀猀 愀琀 愀搀洀椀猀猀椀漀渀 栀愀搀 ㄀⸀㠀㄀ 最爀攀愀琀攀爀 爀椀猀欀 漀昀 洀漀爀琀愀氀椀琀礀⸀ 䌀漀渀挀氀甀猀椀漀渀猀㨀 倀愀琀椀攀渀琀猀 眀椀琀栀 䌀伀관嘀䤀䐀19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more like氀礀 琀漀 戀攀 瀀攀爀昀漀爀洀攀搀 椀渀 漀氀搀攀爀Ⰰ 栀礀瀀攀爀琀攀渀猀椀瘀攀Ⰰ 愀渀搀 椀洀洀甀渀漀猀甀瀀瀀爀攀猀猀攀搀 瀀愀琀椀攀渀琀猀Ⰰ 琀栀漀猀攀 甀猀椀渀最 刀䄀匀ⴀ戀氀漀挀欀椀渀最 搀爀甀最猀Ⰰ 愀渀搀 琀栀漀猀攀 眀椀琀栀 最愀猀琀爀漀ntestinal symptoms. Low hemoglobin is a risk factor for mortality. Creator: Adobe InDesign 16.3 (Windows) Producer: Adobe PDF Library 15.0 CreationDate: Fri Aug 20 06:57:58 CEST 2021 ModDate: Fri Aug 20 06:57:59 CEST 2021 ID: 0xae0a1b33a5974e4495004bb02265ddc2, 0xc2cce73d70064c40b9b0d6283bee20ce Filters: FilterPipeline: FlateDecode FilterPipeline: DCTDecode Images: Image: NisoImageMetadata: FormatName: image/jpg CompressionScheme: JPEG ImageWidth: 821 ImageHeight: 538 ColorSpace: RGB BitsPerSample: 8 BitsPerSampleUnit: integer Intent: RelativeColorimetric Name: X Fonts: Type1: Font: BaseFont: KHEQJU+MinionPro-Bold FontSubset: true FirstChar: 46 LastChar: 54 FontDescriptor: FontName: KHEQJU+MinionPro-Bold Flags: Serif, Nonsymbolic FontBBox: -318, -360, 1684, 917 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true Font: BaseFont: WGNZVW+MyriadPro-Bold FontSubset: true FirstChar: 32 LastChar: 121 FontDescriptor: FontName: WGNZVW+MyriadPro-Bold Flags: Nonsymbolic FontBBox: -92, -250, 1256, 897 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true Font: BaseFont: SIIWRE+MyriadPro-Regular FontSubset: true FirstChar: 32 LastChar: 243 FontDescriptor: FontName: SIIWRE+MyriadPro-Regular Flags: Nonsymbolic FontBBox: -46, -250, 1126, 881 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true Font: BaseFont: RPQGDG+MinionPro-It FontSubset: true FirstChar: 110 LastChar: 116 FontDescriptor: FontName: RPQGDG+MinionPro-It Flags: Serif, Nonsymbolic, Italic FontBBox: -201, -360, 1684, 919 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true Font: BaseFont: JFVUVW+MinionPro-Regular FontSubset: true FirstChar: 27 LastChar: 252 FontDescriptor: FontName: JFVUVW+MinionPro-Regular Flags: Serif, Nonsymbolic FontBBox: -289, -360, 1684, 917 FontFile3: true EncodingDictionary: BaseEncoding: WinAnsiEncoding Differences: true ToUnicode: true Font: BaseFont: KZGVJU+MyriadPro-BoldIt FontSubset: true FirstChar: 58 LastChar: 117 FontDescriptor: FontName: KZGVJU+MyriadPro-BoldIt Flags: Nonsymbolic, Italic FontBBox: -96, -250, 1225, 889 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true Font: BaseFont: VATEHY+MyriadPro-It FontSubset: true FirstChar: 112 LastChar: 112 FontDescriptor: FontName: VATEHY+MyriadPro-It Flags: Nonsymbolic, Italic FontBBox: -112, -250, 1090, 873 FontFile3: true Encoding: WinAnsiEncoding ToUnicode: true TrueType: Font: BaseFont: IEFEHY+Cambria FontSubset: true FirstChar: 32 LastChar: 42 FontDescriptor: FontName: IEFEHY+Cambria Flags: Serif, Nonsymbolic FontBBox: -1475, -2464, 2868, 3117 FontFile2: true Encoding: WinAnsiEncoding ToUnicode: true Font: BaseFont: IEFEHY+SegoeUI FontSubset: true FirstChar: 32 LastChar: 118 FontDescriptor: FontName: IEFEHY+SegoeUI Flags: Nonsymbolic FontBBox: -573, -411, 1999, 1298 FontFile2: true Encoding: WinAnsiEncoding ToUnicode: true XMP: 2021-08-20T06:57:58+02:00 2021-08-20T06:57:59+02:00 2021-08-20T06:57:59+02:00 Adobe InDesign 16.3 (Windows) uuid:fb2df78c-b648-4b7d-b97a-25036a1c6eac adobe:docid:indd:a1ace0ee-97e8-11da-8f16-a6a04fdc746b xmp.id:fd7c1f03-b9a8-3046-b0f8-5c4d1828a768 proof:pdf xmp.iid:690c7aab-87fb-f142-b374-3114a22f10ae xmp.did:bc22386f-af3f-aa45-91c3-3970d882ebca adobe:docid:indd:a1ace0ee-97e8-11da-8f16-a6a04fdc746b default converted from application/x-indesign to application/pdf Adobe InDesign 16.3 (Windows) / 2021-08-20T06:57:58+02:00 application/pdf Román J.L.; García-Carro C.; Agraz I.; Toapanta N.; Vergara A.; Gabaldón A.; Torres I.; Bury R.; Baldallo C.; Serón D.; Soler M.J. COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Introduction: Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Methods: Data included patients who underwent kidney biopsy at the Vall d’Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Results: Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO­VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Conclusions: Patients with CO­VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality. Coronavirus COVID-19 Severe acute respiratory syndrome coronavirus 2 Chronic kidney disease Biopsy-proven kidney disease True https://www.karger.com/Article/FullText/515714#copyright Adobe PDF Library 15.0 False Pages: Page: Label: 452 Sequence: 1 Page: Label: 453 Sequence: 2 Annotations: Annotation: Subtype: Link Rect: 283, 642, 288, 628 ActionDest: 111 Annotation: Subtype: Link Rect: 42, 629, 47, 615 ActionDest: 111 Annotation: Subtype: Link Rect: 71, 604, 76, 590 ActionDest: 111 Annotation: Subtype: Link Rect: 233, 591, 238, 577 ActionDest: 111 Annotation: Subtype: Link Rect: 187, 578, 193, 564 ActionDest: 111 Annotation: Subtype: Link Rect: 93, 527, 99, 513 ActionDest: 111 Annotation: Subtype: Link Rect: 128, 463, 133, 449 ActionDest: 111 Annotation: Subtype: Link Rect: 229, 438, 234, 424 ActionDest: 111 Annotation: Subtype: Link Rect: 195, 400, 200, 386 ActionDest: 111 Annotation: Subtype: Link Rect: 274, 374, 279, 360 ActionDest: 111 Annotation: Subtype: Link Rect: 228, 336, 233, 322 ActionDest: 111 Annotation: Subtype: Link Rect: 202, 259, 207, 245 ActionDest: 111 Annotation: Subtype: Link Rect: 46, 234, 51, 220 ActionDest: 111 Annotation: Subtype: Link Rect: 103, 157, 109, 143 ActionDest: 111 Annotation: Subtype: Link Rect: 484, 718, 489, 704 ActionDest: 111 Page: Label: 454 Sequence: 3 Page: Label: 455 Sequence: 4 Page: Label: 456 Sequence: 5 Annotations: Annotation: Subtype: Link Rect: 228, 106, 233, 92 ActionDest: 111 Annotation: Subtype: Link Rect: 239, 106, 244, 92 ActionDest: 111 Annotation: Subtype: Link Rect: 465, 132, 471, 118 ActionDest: 111 Page: Label: 457 Sequence: 6 Annotations: Annotation: Subtype: Link Rect: 119, 591, 124, 577 ActionDest: 111 Annotation: Subtype: Link Rect: 216, 591, 221, 577 ActionDest: 111 Annotation: Subtype: Link Rect: 70, 565, 76, 551 ActionDest: 111 Annotation: Subtype: Link Rect: 127, 387, 132, 373 ActionDest: 111 Annotation: Subtype: Link Rect: 132, 387, 138, 373 ActionDest: 111 Annotation: Subtype: Link Rect: 245, 349, 250, 335 ActionDest: 111 Annotation: Subtype: Link Rect: 250, 349, 255, 335 ActionDest: 111 Annotation: Subtype: Link Rect: 72, 259, 77, 245 ActionDest: 111 Annotation: Subtype: Link Rect: 77, 259, 83, 245 ActionDest: 111 Annotation: Subtype: Link Rect: 88, 259, 94, 245 ActionDest: 111 Annotation: Subtype: Link Rect: 94, 259, 99, 245 ActionDest: 111 Annotation: Subtype: Link Rect: 195, 259, 200, 245 ActionDest: 111 Annotation: Subtype: Link Rect: 200, 259, 206, 245 ActionDest: 111 Annotation: Subtype: Link Rect: 163, 221, 168, 207 ActionDest: 111 Annotation: Subtype: Link Rect: 168, 221, 173, 207 ActionDest: 111 Annotation: Subtype: Link Rect: 105, 183, 110, 169 ActionDest: 111 Annotation: Subtype: Link Rect: 110, 183, 115, 169 ActionDest: 111 Annotation: Subtype: Link Rect: 120, 183, 125, 169 ActionDest: 111 Annotation: Subtype: Link Rect: 125, 183, 130, 169 ActionDest: 111 Annotation: Subtype: Link Rect: 212, 157, 217, 143 ActionDest: 111 Annotation: Subtype: Link Rect: 217, 157, 222, 143 ActionDest: 111 Annotation: Subtype: Link Rect: 276, 119, 282, 105 ActionDest: 111 Annotation: Subtype: Link Rect: 282, 119, 287, 105 ActionDest: 111 Annotation: Subtype: Link Rect: 451, 438, 456, 424 ActionDest: 111 Annotation: Subtype: Link Rect: 461, 438, 466, 424 ActionDest: 111 Annotation: Subtype: Link Rect: 307, 361, 313, 347 ActionDest: 111 Annotation: Subtype: Link Rect: 445, 285, 450, 271 ActionDest: 111 Annotation: Subtype: Link Rect: 450, 285, 456, 271 ActionDest: 111 Page: Label: 458 Sequence: 7 Annotations: Annotation: Subtype: Link Rect: 42, 294, 55, 284 ActionDest: 1 Annotation: Subtype: Link Rect: 108, 285, 154, 274 Annotation: Subtype: Link Rect: 42, 266, 55, 255 ActionDest: 1 Annotation: Subtype: Link Rect: 156, 266, 204, 255 Annotation: Subtype: Link Rect: 55, 256, 130, 246 Annotation: Subtype: Link Rect: 42, 218, 55, 208 ActionDest: 1 Annotation: Subtype: Link Rect: 55, 190, 77, 179 Annotation: Subtype: Link Rect: 42, 180, 55, 170 ActionDest: 1 Annotation: Subtype: Link Rect: 113, 142, 179, 132 Annotation: Subtype: Link Rect: 216, 294, 229, 284 ActionDest: 1 Annotation: Subtype: Link Rect: 344, 275, 378, 265 Annotation: Subtype: Link Rect: 229, 266, 257, 255 Annotation: Subtype: Link Rect: 216, 256, 229, 246 ActionDest: 1 Annotation: Subtype: Link Rect: 255, 228, 300, 217 Annotation: Subtype: Link Rect: 216, 218, 229, 208 ActionDest: 1 Annotation: Subtype: Link Rect: 251, 180, 287, 170 Annotation: Subtype: Link Rect: 216, 171, 229, 160 ActionDest: 1 Annotation: Subtype: Link Rect: 365, 123, 378, 113 Annotation: Subtype: Link Rect: 229, 114, 255, 103 Annotation: Subtype: Link Rect: 391, 294, 403, 284 ActionDest: 1 Annotation: Subtype: Link Rect: 484, 275, 530, 265 Annotation: Subtype: Link Rect: 455, 237, 478, 227 Annotation: Subtype: Link Rect: 437, 190, 501, 179 Annotation: Subtype: Link Rect: 516, 152, 531, 141 Page: Label: 459 Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 119, 712, 180, 702 Annotation: Subtype: Link Rect: 190, 665, 204, 654 Annotation: Subtype: Link Rect: 55, 655, 72, 645 Annotation: Subtype: Link Rect: 291, 703, 341, 692 Annotation: Subtype: Link Rect: 356, 665, 378, 654 Annotation: Subtype: Link Rect: 229, 655, 267, 645 Annotation: Subtype: Link Rect: 446, 703, 529, 692 Annotation: Subtype: Link Rect: 469, 636, 491, 626 Checksum: 073a0c65 Type: CRC32 Checksum: 2105744368932a2d2ccf7c1786f339a5 Type: MD5 Checksum: 430474149737eb0013ece34d5538064abfca2628 Type: SHA-1